Algert Global LLC Trims Holdings in Maximus, Inc. $MMS

Algert Global LLC lowered its stake in shares of Maximus, Inc. (NYSE:MMS) by 24.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 136,220 shares of the health services provider’s stock after selling 44,536 shares during the period. Algert Global LLC owned 0.24% of Maximus worth $12,446,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in MMS. Richardson Financial Services Inc. increased its stake in Maximus by 123.1% during the third quarter. Richardson Financial Services Inc. now owns 348 shares of the health services provider’s stock worth $32,000 after acquiring an additional 192 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in Maximus during the second quarter worth about $35,000. Cullen Frost Bankers Inc. purchased a new position in Maximus during the third quarter worth about $38,000. Parkside Financial Bank & Trust increased its position in shares of Maximus by 27.2% during the third quarter. Parkside Financial Bank & Trust now owns 1,118 shares of the health services provider’s stock valued at $102,000 after acquiring an additional 239 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Maximus by 13.9% during the third quarter. GAMMA Investing LLC now owns 1,337 shares of the health services provider’s stock valued at $122,000 after acquiring an additional 163 shares during the last quarter. 97.21% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on MMS shares. Zacks Research upgraded shares of Maximus from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 30th. Weiss Ratings lowered Maximus from a “buy (b)” rating to a “hold (c+)” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen cut Maximus from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy”.

Insider Activity at Maximus

In related news, CFO David Mutryn bought 1,000 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were purchased at an average cost of $75.62 per share, with a total value of $75,620.00. Following the transaction, the chief financial officer directly owned 40,037 shares of the company’s stock, valued at approximately $3,027,597.94. This represents a 2.56% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Bruce Caswell purchased 3,175 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were bought at an average price of $78.45 per share, for a total transaction of $249,078.75. Following the completion of the purchase, the chief executive officer directly owned 328,013 shares in the company, valued at $25,732,619.85. This represents a 0.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.80% of the stock is currently owned by insiders.

Maximus Price Performance

Shares of NYSE MMS opened at $72.40 on Monday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.34 and a quick ratio of 2.34. The company has a market cap of $3.95 billion, a price-to-earnings ratio of 11.02 and a beta of 0.59. The stock’s 50-day moving average is $84.50 and its two-hundred day moving average is $85.67. Maximus, Inc. has a 1-year low of $64.68 and a 1-year high of $100.00.

Maximus (NYSE:MMS) last issued its quarterly earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.84 by $0.01. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.37 billion. Maximus had a net margin of 6.92% and a return on equity of 25.30%. The firm’s quarterly revenue was down 4.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.61 earnings per share. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. Analysts forecast that Maximus, Inc. will post 6.15 EPS for the current fiscal year.

Maximus Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were given a dividend of $0.33 per share. The ex-dividend date was Friday, February 13th. This represents a $1.32 annualized dividend and a dividend yield of 1.8%. This is a boost from Maximus’s previous quarterly dividend of $0.30. Maximus’s payout ratio is presently 20.09%.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.